Eli Lilly's Tirzepatide Becomes World's Best-Selling Drug

In-Depth Analysis

Eli Lilly (LLY) is experiencing significant growth driven by its GLP-1 drug, tirzepatide. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, tirzepatide has quickly become the world's best-selling drug, surpassing Merck's Keytruda. In the U.S. incretin analog market, Eli Lilly holds a 57.9% share of total prescriptions.

The company's Q3 2025 revenues increased by 54% year-over-year to $17.6 billion, with adjusted EPS soaring by 495% to $7.02. Eli Lilly has raised its full-year revenue guidance to $63 billion - $65 billion. It is also developing an oral GLP-1 candidate, orforglipron, which has shown promising results in Phase 3 trials. If approved, this could further boost Eli Lilly's market share. The company is awaiting results from Phase 3 trials for another GLP-1 candidate, retatrutide, expected by the end of 2026.

Eli Lilly's success in the GLP-1 market is driven by the high clinical need for effective diabetes and weight loss treatments. With a diversified portfolio that includes drugs for oncology, immunology, and neuroscience, Eli Lilly is poised for continued growth.

**Actionable Takeaways:** - Monitor Eli Lilly's progress in securing regulatory approval for orforglipron. - Keep an eye on the results of the ATTAIN-MAINTAIN phase 3 study evaluating orforglipron as a maintenance therapy for weight loss. - Track the development of retatrutide and its potential impact on the weight loss market.

Read source article

FAQ

What is tirzepatide?

Tirzepatide is a GLP-1 dual receptor agonist manufactured by Eli Lilly, sold as Mounjaro for type 2 diabetes and Zepbound for weight loss.

How has tirzepatide performed in the market?

Tirzepatide became the world's best-selling drug in Q3 2025, with $10.1 billion in sales. Mounjaro's U.S. prescriptions rose by over 60%, and Zepbound prescriptions tripled year-over-year in Q3.

Takeaways

Eli Lilly's tirzepatide has become the world's best-selling drug, driven by the increasing demand for GLP-1-based treatments. The company's strong financial performance and diversified portfolio suggest continued growth potential. Key actions for readers include monitoring the development of Eli Lilly's oral GLP-1 candidate and tracking the company's progress in the incretin analog market.

Discussion

Do you think Eli Lilly will maintain its lead in the GLP-1 market? Share your thoughts below! Share this article with others who need to stay ahead of this trend!

Sources

This Company Now Has the World's No. 1 Drug. Should You Invest $1,000? 2 Reasons I'm Keeping My Eye on Eli Lilly Stock Right Now Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine

Disclaimer

This article was compiled by Yanuki using publicly available data and trending information. The content may summarize or reference third-party sources that have not been independently verified. While we aim to provide timely and accurate insights, the information presented may be incomplete or outdated.

All content is provided for general informational purposes only and does not constitute financial, legal, or professional advice. Yanuki makes no representations or warranties regarding the reliability or completeness of the information.

This article may include links to external sources for further context. These links are provided for convenience only and do not imply endorsement.

Always do your own research (DYOR) before making any decisions based on the information presented.